Myriad Genetics beats by $0.05, beats on revs; guides Q2 EPS below consensus, revs below consensus; reaffirms FY18 EPS guidance, revs guidance (29.901 -0.40)
- Reports Q1 (Sep) earnings of $0.26 per share, excluding non-recurring items, $0.05 better than the Capital IQ Consensus of $0.21; revenues rose 7.2% year/year to $190.2 mln vs the $183.52 mln Capital IQ Consensus.
- Co issues downside guidance for Q2, sees EPS of $0.22-0.24, excluding non-recurring items, vs. $0.25 Capital IQ Consensus Estimate; sees Q2 revs of $187-189 mln vs. $189.39 mln Capital IQ Consensus Estimate.
- Co reaffirms guidance for FY18, sees EPS of $1.00-1.05, excluding non-recurring items, vs. $1.03 Capital IQ Consensus Estimate; sees FY18 revs of $750-770 mln vs. $765.01 mln Capital IQ Consensus Estimate.